Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezutromid - Summit Therapeutics

Drug Profile

Ezutromid - Summit Therapeutics

Alternative Names: BMN-195; SMT-1100; SMTC-1100; VOX-C1100

Latest Information Update: 17 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VASTox
  • Developer Summit Therapeutics
  • Class Benzoxazoles; Naphthalenes; Small molecules; Sulfoxides
  • Mechanism of Action Utrophin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 27 Aug 2018 Summit Therapeutics completes a phase II clinical trials in Duchenne muscular dystrophy (In children) in United Kingdom and USA (PO) (EudraCT2015-004333-27) (NCT02858362)
  • 27 Jun 2018 Summit Therapeutics withdraws a phase II trial for Duchenne muscular dystrophy in USA and Europe prior to enrolment
  • 27 Jun 2018 Discontinued - Phase-I for Duchenne muscular dystrophy (In adults) in United Kingdom following failure to meet primary endpoint (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top